Jiangsu Hengrui Medicine
600276.SS
#434
Rank
S$69.81 B
Marketcap
S$10.52
Share price
-1.46%
Change (1 day)
27.65%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2025 (TTM): S$0.17

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is S$0.16. In 2024 the company made an earnings per share (EPS) of S$0.17 an increase over its 2023 EPS that were of S$0.12.

EPS history for Jiangsu Hengrui Medicine from 2000 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$0.17-1.36%
2024S$0.1742.43%
2023S$0.128.77%
2022S$0.11-20.62%
2021S$0.14-26.59%
2020S$0.1927.24%
2019S$0.1528.41%
2018S$0.1220.04%
2017S$0.0985531.21%
2016S$0.0751011.46%
2015S$0.0673836.27%
2014S$0.0494519.77%
2013S$0.0412918.05%
2012S$0.0349723.9%
2011S$0.0282326.9%
2010S$0.0222412.37%
2009S$0.0198056.6%
2008S$0.012649.18%
2007S$0.01158114.48%
2006S$0.00539864.83%
2005S$0.00327535.55%
2004S$0.00241629.73%
2003S$0.00186219.86%
2002S$0.001554-2.71%
2001S$0.0015971.02%
2000S$0.001581